ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$256.73
−1.34%Sep 4, 2026, 15:53 UTC
AbbVie announced that its drug etentamig met key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
Source:Sep 3, 2026, 13:24 UTC
AbbVie completed its $11 billion acquisition of Apogee Therapeutics.
Source:Sep 3, 2026, 13:15 UTC
AbbVie announced that its CERVINO Phase 3 trial met dual primary endpoints, with full results to be presented from September 23 to 26.
Sep 1, 2026, 12:05 UTC
Allergan Aesthetics, an AbbVie company, launched SkinMedica Barrier Calming Cream and HA5 Hydra Collagen Facial Mist as new regenerative skincare products in Irvine, California, on September 1, 2026.
Source:Aug 28, 2026, 00:18 UTC
China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.
Source:Aug 27, 2026, 06:00 UTC
AbbVie submitted a regulatory application to the European Medicines Agency seeking approval for SKYRIZI (risankizumab) subcutaneous induction for adults with moderately to severely active Crohn's disease, supported by data from the Phase 3 AFFIRM study.
Source:Aug 25, 2026, 15:45 UTC
Richard Gonzalez, former CEO of AbbVie, listed his Trump Tower condo for sale at $3.9 million.
Source:Aug 25, 2026, 08:09 UTC
Donaldson Capital Management LLC increased its stake in AbbVie Inc. by 0.7% during the quarter, acquiring 3,553 additional shares, bringing its total holdings to 485,608 shares valued at $122.20 million.
Source:Aug 25, 2026, 08:09 UTC
Convergence Financial LLC increased its stake in AbbVie Inc. by 91.7% during the quarter, acquiring an additional 2,713 shares to hold 5,670 shares, as disclosed in an SEC filing.
Source:Aug 24, 2026, 00:00 UTC
Oruka Therapeutics, Inc. appointed Todd Edwards as Chief Commercial Officer, effective with a base salary of $525,000, a target bonus of 40% of annual base salary, a signing bonus of $200,000, and equity grants including a stock option for 20,000 shares and restricted stock units for 100,000 shares of Oruka common stock.
Aug 23, 2026, 08:41 UTC
Gateway Wealth Partners LLC reduced its stake in AbbVie Inc. by 40.8% during the second quarter, selling 11,835 shares and retaining 17,158 shares, as disclosed in a recent SEC filing.
Source:Aug 22, 2026, 09:45 UTC
AbbVie EVP Nicholas Donoghoe sold 32,710 shares of AbbVie stock in a transaction on August 14th.
Source:Aug 21, 2026, 11:48 UTC
AbbVie presented clinical data from its lung cancer research programs at the 2026 World Conference on Lung Cancer, including Phase 1b results for ABBV-1480 and a Phase 1b/2 study for telisotuzumab adizutecan.
Source:Aug 21, 2026, 11:30 UTC
AbbVie announced a modified Dutch auction tender offer to repurchase up to $230 million of its common stock.
Source:Aug 19, 2026, 19:38 UTC
Biopharma stocks including AbbVie, Amgen, Eli Lilly, Johnson & Johnson, and Merck rallied on Wednesday, with Merck jumping 12.4%.
Source:Aug 16, 2026, 13:57 UTC
Zelgen Biopharmaceuticals reached a BD collaboration with AbbVie on ZG006, recognizing 662 million yuan in technology licensing revenue, with both parties accelerating global development.
Aug 6, 2026, 19:00 UTC
The Trump administration quietly changed a policy that delayed Medicare price negotiations for an AbbVie drug by seven years, according to an advocacy group's analysis.
Source:Aug 6, 2026, 00:00 UTC
REGENXBIO Inc. received a $100 million milestone payment from AbbVie for the first patient dosing in the NAAVIGATE trial.
Source:Aug 5, 2026, 09:57 UTC
Rongchang Biologics signed an exclusive licensing agreement with AbbVie, granting AbbVie exclusive rights to develop, produce, and commercialize RC148 outside Greater China.
Aug 4, 2026, 13:09 UTC
AbbVie Inc. is seeking to raise at least $8 billion through an investment-grade bond offering to fund part of its acquisition of Apogee Therapeutics Inc.
Source:Aug 4, 2026, 12:00 UTC
Allergan Aesthetics, an AbbVie company, announced that the U.S. FDA has accepted for review its supplemental Biologics License Application for BOTOX Cosmetic for the temporary improvement of masseter muscle prominence in adults.
Source:Aug 3, 2026, 14:05 UTC
AbbVie Inc. stock reached a 52-week high of $267.47 on June 29, 2026.
Source:Jul 31, 2026, 11:47 UTC
AbbVie reported second-quarter 2026 financial results with diluted EPS of $2.03 on a GAAP basis and adjusted diluted EPS of $3.65, and net revenues of $16.990 billion, an increase of 10.2 percent on a reported basis.
Jul 9, 2026, 14:01 UTC
West Pharmaceutical Services completed the sale of its SmartDose 3.5mL platform to AbbVie.
Source:
Page 1Next →